Cytochrome P-450 metabolic-intermediate complex formation with a series of diphenhydramine analogues

[1]  J. Noordhoek,et al.  Effect of multiple administration of orphenadrine or mono-N-desmethylorphenadrine on cytochrome P-450 catalyzed reactions in the rat , 1983, Archives of Toxicology.

[2]  D. Pessayre,et al.  Formation of an inactive cytochrome P-450Fe(II)-metabolite complex after administration of amiodarone in rats, mice and hamsters. , 1986, Biochemical pharmacology.

[3]  B. Lindeke,et al.  CYTOCHROME P-450 COMPLEX FORMATION IN THE METABOLISM OF PHENYLALKYLAMINES. 8. TEREOSELECTIVITY IN METABOLIC INTERMEDIARY COMPLEX FORMATION WITH A SERI S OF CHIRAL 2-SUBSTITUTED 1-PHENYL-2-AMINOETHANES , 1984 .

[4]  J. Noordhoek,et al.  Relationship Between Molecular Structure and Cytochrome P450−Metabolic Intermediate Complex Formation , 1984 .

[5]  K. Jönsson,et al.  Cytochrome P-455 nm complex formation in the metabolism of phenylalkylamines. 8. Stereoselectivity in metabolic intermediary complex formation with a series of chiral 2-substituted 1-phenyl-2-aminoethanes. , 1984, Journal of medicinal chemistry.

[6]  J. Noordhoek,et al.  Product inhibition in orphenadrine metabolism as a result of a stable cytochrome P-450-metabolic intermediate complex formed during the disposition of mono-N-desmethylorphenadrine (tofenacine) in the rat. , 1983, Research communications in chemical pathology and pharmacology.

[7]  D. Pessayre,et al.  Formation of inactive cytochrome P-450 Fe(II)-metabolite complexes with several erythromycin derivatives but not with josamycin and midecamycin in rats. , 1983, Biochemical pharmacology.

[8]  L. Pershing,et al.  Cytochrome P-450 metabolic-intermediate complex formation and induction by macrolide antibiotics; a new class of agents. , 1982, Xenobiotica; the fate of foreign compounds in biological systems.

[9]  J. Noordhoek,et al.  Spectral interaction of orphenadrine and its metabolites with oxidized and reduced hepatic microsomal cytochrome P-450 in the rat. , 1982, Biochemical pharmacology.

[10]  C. Wolf,et al.  Quantitation of two forms of pulmonary cytochrome P-450 in microsomes, using substrate specificities. , 1980, Molecular pharmacology.

[11]  Rf Rekker,et al.  THE HYDROPHOBIC FRAGMENTAL CONSTANT; AN EXTENSION TO A 1000 DATA POINT SET , 1979 .

[12]  S. Orrenius,et al.  Cytochrome P450 product complexes and glutathione consumption produced in isolated hepatocytes by norbenzphetamine and its N-oxidized congeners. , 1979, Biochemical pharmacology.

[13]  M. Franklin.  Inhibition of mixed-function oxidations by substrates forming reduced cytochrome P-450 metabolic-intermediate complexes , 1977 .

[14]  C. Hansch.  Quantitative Relationships Between Lipophilic Character and Drug Metabolism , 1972 .